FDMT

4D Molecular Therapeutics Inc

FDMT, USA

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

https://www.4dmoleculartherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
FDMT
stock
FDMT

Is 4D Molecular Therapeutics Inc (FDMT) positioned for future growth? Setenews

Read more →
FDMT
stock
FDMT

The Technical Signals Behind (FDMT) That Institutions Follow news.stocktradersdaily.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$33.1111

Analyst Picks

Strong Buy

5

Buy

4

Hold

2

Sell

0

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Low

1.62

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-15.41 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-13.41 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-51,765.56 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.15

Low 1

High 0.3

Investors

* Institutions hold a combined 98.41% of the total shares of 4D Molecular Therapeutics Inc

1.

Bvf Inc

(9.9123%)

since

2025/06/30

2.

RA Capital Management, LLC

(9.7708%)

since

2025/06/30

3.

Goldman Sachs Group Inc

(8.9059%)

since

2025/06/30

4.

BlackRock Inc

(8.5879%)

since

2025/06/30

5.

Vanguard Group Inc

(5.8598%)

since

2025/06/30

6.

Novo A/S

(4.2824%)

since

2025/06/30

7.

HHG PLC

(3.7566%)

since

2025/06/30

8.

Federated Hermes Inc

(3.5701%)

since

2025/06/30

9.

Vanguard Total Stock Mkt Idx Inv

(3.2209%)

since

2025/07/31

10.

Millennium Management LLC

(3.177%)

since

2025/06/30

11.

Federated Hermes MDT SCC Institutional

(2.3988%)

since

2025/06/30

12.

Federated Hermes MDT Small Cap Core IS

(2.3988%)

since

2025/06/30

13.

iShares Russell 2000 ETF

(2.1444%)

since

2025/08/31

14.

State Street Corp

(2.0598%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.9799%)

since

2025/06/30

16.

Geode Capital Management, LLC

(1.9668%)

since

2025/06/30

17.

Bank of America Corp

(1.9208%)

since

2025/06/30

18.

JPMorgan Chase & Co

(1.9014%)

since

2025/06/30

19.

Janus Henderson Global Life Sciences

(1.7883%)

since

2025/06/30

20.

Janus Henderson Global Life Sciences D

(1.7883%)

since

2025/06/30

21.

Two Sigma Advisers, LLC

(1.5918%)

since

2025/06/30

22.

Janus Global Life Science AUSD

(1.5372%)

since

2025/06/30

23.

Janus Henderson Glb Life Scn I2 USD

(1.5238%)

since

2025/07/31

24.

Assenagon Asset Management SA

(1.3893%)

since

2025/06/30

25.

Two Sigma Investments LLC

(1.1373%)

since

2025/06/30

27.

Fidelity Small Cap Index

(0.8675%)

since

2025/06/30

28.

Federated Hermes MDT SCG Institutional

(0.8466%)

since

2025/06/30

29.

Federated Hermes MDT Small Cap Growth IS

(0.8466%)

since

2025/06/30

30.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7552%)

since

2025/07/31

31.

iShares Russell 2000 Value ETF

(0.7457%)

since

2025/08/31

32.

Northern Trust Corp

(0.7044%)

since

2025/06/30

33.

Peapod Lane Capital LLC

(0.6821%)

since

2025/06/30

34.

Invesco Technology S&P US Sel Sec ETF

(0.6502%)

since

2025/07/31

35.

iShares Biotechnology ETF

(0.5254%)

since

2025/08/31

36.

JPM Thematics Genetic Thrps C2 dist USD

(0.5134%)

since

2025/07/31

37.

DWS ESG Biotech LC

(0.424%)

since

2025/07/31

38.

Vanguard Russell 2000 ETF

(0.4054%)

since

2025/07/31

39.

Fidelity Extended Market Index

(0.3912%)

since

2025/07/31

40.

State St Russell Sm Cap® Indx SL Cl I

(0.3813%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.532

Latest Release

Date

2025-09-30

EPS Actual

-1.01

EPS Estimate

-1.01

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(4.5)
Growth
Weak Growth Prospect(3)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Fair Value(4.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.